## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE Group Art Unit 1648 Examiner: SMIT et al. Budens Inventor(s): 807.506 Atty. Dkt. Appln. No.: PMS 236842 B041089MRZ Series Code 个 Serlal No. 个 Client Ref (Our Deposit Account No. 03-3975) February 27, 1997 Filed: **GRADUAL MODIFICATION...** Title: (Our Order No. Asst. Commissioner of Patents June 23, 1999 Date: Washington, D.C. 20231

## REPLY/AMENDMENT/LETTER

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and select which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED 1. "Small Entity" statement(s) filed □ previously Claims **Highest number** Present Extra Large/Small Entity Additional Fee previously paid for herewith remaining after Code (No.) amendment \*\*minus 2. Total Effective Claims x \$18/\$9 =103/203 \*\*\*minus 4 3. Independent Claims x \$78/\$39 =102/202 4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application)..... .....add + \$260/\$130 = 104/204 NONE 5. Original due Date: JULY 9, 1999 6. Petition is hereby made to extend the original (1 mo) \$110/\$55 = 115/215 due date to cover the date this response is filed \$380/\$190 = +0116/216 (2 mos) 117/217 \$870/\$435 = for which the requisite fee is attached (3 mos) 7. Enter any previous extension fee paid since above original due date and subtract 11 **Extension Fee Attached** 9. If Terminal Disclaimer attached, add Rule 20(d) official fee ...... + \$/\$ = +0148/248 + \$ = 126 + 0 122 or if Rule 97(d) Petition ......add + \$ = 11. After-Final Request Fee per rules 129(a) and 17(r) ..... + \$760/380 = +0 146/246 12. No. of additional inventions for examination per Rule 129(b) ..... x \$760/380 ea =+ 0 149/249 13. Petition fee for +014. TOTAL FEE ENCLOSED = \$0 15. \*If the entry in this space is less than entry in next space, the "Present Extra" result is "0".

16. \*\* If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

17. \*\*\*If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown in the heading hereof, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

36830

**Pillsbury Madison & Sutro LLP Intellectual Property Group** 

1100 New York Avenue, N.W. Ninth Floor East Tower

Washington, D.C. 20005-3918

Tel: (202) 861-3000 Atty/Sec: ASH/maf

Sir:

By Atty: Ann S. Hobbs, Ph.D. Sig:

Fax:

Reg. No.

(202) 822-0944

(202) 861-3063

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JUN 2 3 1999

In re Application of SMIT et al.

08/807 Application No.:

February 27, 1997 Filed:

Group Art Unit;

Examiner: Budens

For: GRADUAL MODIFICATION, SUPER AGONISTS AND ANTAGONISTS OF SIGNAL-PROTEINS AND PEPTIDES

## **AMENDMENT**

Honorable Commissioner of Patents and Trademarks Washington, D.C. 20231

June 23, 1999

Sir:

In response to the Communication issued June 9, 1999, please enter the following amendments and consider the following remarks.

## IN THE CLAIMS:

Cancel claims 55-75 and 77-93 without prejudice and enter the following claims:

--94. A method for quantitative/structure function analysis research on biologically active proteins or peptides, said method comprising applying a specific chemical modification of selected amino/acids to introduce at least one feature selected from the group consisting of enhanced biological activity, enhanced stability, suppressed antigenicity, acquired antagonistic activity, and cell inhibitory activity is/introduced into said proteins or peptides, said method comprising the steps of 07/01/1999 BFRIESON 00a)00gradual&chemical modification of a protein or peptide, foliowed by

01 FC:103